Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.

Oncologist · 2023 · PMC9847561 · PMID 36181764

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

However, the authors concluded that nimotuzumab demonstrated a clear trend of efficacy and excellent safety in patients with MGMT promoter unmethylated glioblastoma. 14 Our findings are similar to that of Westphal.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.